BOSTON, June 11, 2025 /PRNewswire/ – Taiwan is making a significant investment in biotechnology innovation and global partnerships at the upcoming BIO International Convention 2025, taking place June 16–19 in Boston. Spearheaded by the Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO), under the Ministry of Economic Affairs, Taiwan’s delegation is poised to demonstrate its advancements and solidify its position as a leading biotech hub. The central element of this effort is the Taiwan Pavilion, strategically themed "Taiwan, Your Best Partner in Asia," and designed to attract international attention and foster collaborative opportunities. This year’s pavilion brings together a robust coalition of 35 companies, one industry association, and six leading research institutes, collectively showcasing the cutting-edge developments shaping the future of healthcare and biotechnology. Building upon the considerable success of BIO 2024 – which welcomed 19,608 attendees and facilitated 61,508 valuable business matchmaking meetings – Taiwan’s participation is focused on expanding its global influence and driving innovation across key sectors. The pavilion’s core focus is "Full-Age Precision Medicine," a comprehensive approach encompassing over 50 technologies specifically tailored to address healthcare needs throughout the entire lifespan. This initiative underscores Taiwan’s commitment to proactive and holistic healthcare solutions. A cornerstone of Taiwan’s biotech strength lies in its unique blend of artificial intelligence (AI) expertise and advanced biomanufacturing capabilities. The delegation leverages AI to revolutionize medical informatics, leading to the development of sophisticated smart healthcare solutions. Simultaneously, Taiwan’s biomanufacturing prowess supports the global production of pharmaceuticals, highlighting a critical component of the region’s supply chain. These combined strengths position Taiwan as a global leader in several key areas, including regenerative medicine, innovative medical devices, and the provision of Contract Development and Manufacturing Organization (CDMO) services.

Adding further momentum to Taiwan’s presence at the convention is the selection of two promising Taiwanese biotech startups, AnHorn Medicines and Pharmasaga Company Limited, as finalists in the prestigious Start-Up Stadium competition. This global competition, which attracted 57 teams from around the world, offers these companies a crucial platform to engage with leading pharmaceutical executives and venture capital investors. This engagement presents invaluable opportunities for strategic partnerships and potential access to vital funding, ultimately fueling their growth and innovation. To maximize engagement and facilitate networking, Taiwan has meticulously planned several key events surrounding its participation in BIO 2025. Attendees are invited to attend the "Global Innovation Hub – Taiwan" session on Tuesday, June 17th from 3:15–3:30 p.m. in Meeting Room 152, a focused session showcasing Taiwan’s groundbreaking biomedical breakthroughs and identifying collaborative opportunities across industry, government, academia, and clinical sectors. Furthermore, a dedicated "Taiwan Pavilion Networking Event" will be held on Wednesday, June 18th, from 4:00–5:00 p.m. at Booths 1545 & 1645. This event promises an open and welcoming environment for global biotech leaders, complete with a Happy Hour and a showcase of next-generation technologies, innovative products, and emerging cross-border collaboration opportunities.

The Taiwan Pavilion itself, located at Booth No. 1545 & 1645, serves as a central hub for exploring the diverse range of biotech companies participating in the convention. Coordinated by BPIPO, the pavilion actively promotes global partnerships within the biotech, CDMO, and precision health domains. The exhibited technologies encompass a broad spectrum, including cell and gene therapy, novel drug development, smart medical devices, and integrated healthcare solutions designed to support all stages of the healthcare journey. As BIO 2025 approaches, Taiwan’s delegation is fully prepared to demonstrate its biotechnology strengths, strategic vision, and commitment to shaping the future of the global healthcare industry. For more detailed information and to access delegation links, please visit bravotaiwan.tw or contact BPIPO directly.